Cite
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
MLA
Dimopoulos, M. A., et al. “Long-Term Follow-up on Overall Survival from the MM-009 and MM-010 Phase III Trials of Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.” Leukemia (08876924), vol. 23, no. 11, Nov. 2009, pp. 2147–52. EBSCOhost, https://doi.org/10.1038/leu.2009.147.
APA
Dimopoulos, M. A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., Knight, R. D., & Weber, D. M. (2009). Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (08876924), 23(11), 2147–2152. https://doi.org/10.1038/leu.2009.147
Chicago
Dimopoulos, M. A., C. Chen, A. Spencer, R. Niesvizky, M. Attal, E. A. Stadtmauer, M. T. Petrucci, et al. 2009. “Long-Term Follow-up on Overall Survival from the MM-009 and MM-010 Phase III Trials of Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.” Leukemia (08876924) 23 (11): 2147–52. doi:10.1038/leu.2009.147.